Non-iminosugar glucocerebrosidase small molecule chaperones.

Small molecule chaperones are a promising therapeutic approach for the Lysosomal Storage Disorders (LSDs). Here, we report the discovery of a new series of non-iminosugar glucocerebrosidase inhibitors with chaperone capacity, and describe their structure activity relationship (SAR), selectivity, cell activity phamacokinetics.

DNA-PK is involved in repairing a transient surge of DNA breaks induced by deceleration of DNA replication.

Cells that suffer substantial inhibition of DNA replication halt their cell cycle via a checkpoint response mediated by the PI3 kinases ATM and ATR. It is unclear how cells cope with milder replication insults, which are under the threshold for ATM and ATR activation. A third PI3 kinase, DNA-dependent protein kinase (DNA-PK), is also activated following replication inhibition, but the role DNA-PK might play in response to perturbed replication is unclear, since this kinase does not activate the signaling cascades involved in the S-phase checkpoint. Here we report that mild, transient drug-induced perturbation of DNA replication rapidly induced DNA breaks that promptly disappeared in cells that contained a functional DNA-PK whereas such breaks persisted in cells that were deficient in DNA-PK activity. After the initial transient burst of DNA breaks, cells with a functional DNA-PK did not halt replication and continued to synthesize DNA at a slow pace in the presence of replication inhibitors. In contrast, DNA-PK deficient cells subject to low levels of replication inhibition halted cell cycle progression via an ATR-mediated S-phase checkpoint. The ATM kinase was dispensable for the induction of the initial DNA breaks. These observations suggest that DNA-PK is involved in setting a high threshold for the ATR-Chk1-mediated S-phase checkpoint by promptly repairing DNA breaks that appear immediately following inhibition of DNA replication.

High-content kinetic calcium imaging in drug-sensitive and drug-resistant human breast cancer cells.

Intracellular calcium (Ca2+) is involved in the regulation of a variety of biological functions in cancer cells, including growth inhibition, tumor invasiveness, and drug resistance. To gain insight into the possible role played by Ca2+ in the development of drug resistance in breast cancer, we performed a comparative high-content analysis of the intracellular Ca2+ dynamics in drug-sensitive human breast cancer MCF-7 cells and five drug-resistant, MCF-7-derived clonal cell lines. Fura-2 single cell ratiometric fluorescence microscopy was used to monitor real-time quantitative changes in cytosolic-free Ca2+ concentration ( [Ca2+]i ) upon addition of phosphoinositol-coupled receptor agonists. While the magnitude and the onset kinetics of the [Ca2+]i rise were similar in drug-sensitive and drug-resistant cell lines, the decay kinetics of the [Ca2+]i increase was found to be consistently slower in drug-resistant than drug-sensitive cells. Such a delay in reestablishing homeostatic [Ca2+]i persisted in the absence of extracellular Ca2+ and was independent of the expression or function of specific drug efflux pumps associated with drug resistance. Moreover, intracellular Ca2+ pools releasable by phosphoinositol-coupled receptor agonists or thapsigargin appeared to be differentially shared in drug-sensitive and drug-resistant cells. In light of the clinical relevance that drug resistance has in the treatment of cancer, the molecular and biochemical relationship between alterations in Ca2+ dynamics and drug resistance demands to be further investigated and tested in a wider array of cell types. Automated microscopy will help greatly in this pursuit by facilitating both sample imaging and data analysis, thus allowing high-content as well as high-throughput screening of large sample sets. A protocol for studying [Ca2+]i kinetics with a commercially available automated imaging platform is described.